Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Tyvaso® (treprostinil) – New indication
April 1, 2021 - United Therapeutics announced the FDA approval of Tyvaso (treprostinil), for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
